NASDAQ:CLBS

Caladrius Biosciences Stock Forecast, Price & News

$1.20
-0.04 (-3.23 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.20
$1.24
50-Day Range
$1.15
$1.52
52-Week Range
$1.15
$4.89
Volume203,894 shs
Average Volume2.60 million shs
Market Capitalization$71.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
30 days | 90 days | 365 days | Advanced Chart
Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Caladrius Biosciences logo

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes CLBS12, CLBS14, CLBS16 and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

821st out of 1,350 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

14th out of 20 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

Is Caladrius Biosciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Caladrius Biosciences stock.
View analyst ratings for Caladrius Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Caladrius Biosciences?

Wall Street analysts have given Caladrius Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Caladrius Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Caladrius Biosciences?

Caladrius Biosciences saw a decline in short interest in August. As of August 13th, there was short interest totaling 1,660,000 shares, a decline of 13.1% from the July 29th total of 1,910,000 shares. Based on an average daily trading volume, of 451,600 shares, the short-interest ratio is presently 3.7 days. Approximately 2.9% of the shares of the company are short sold.
View Caladrius Biosciences' Short Interest
.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Caladrius Biosciences
.

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) announced its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.05.
View Caladrius Biosciences' earnings history
.

How has Caladrius Biosciences' stock been impacted by COVID-19?

Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLBS stock has decreased by 46.4% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CLBS?

2 equities research analysts have issued 1 year price targets for Caladrius Biosciences' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Caladrius Biosciences' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts' price targets for Caladrius Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the following people:
  • David J. Mazzo, President, Chief Executive Officer & Director
  • Gregory S. Berkin, Chief Information Officer, VP-Cybersecurity & IT
  • Robert M. Honigberg, Chief Medical Officer
  • Todd C. Girolamo, Secretary, Senior Vice President & General Counsel
  • John D. Menditto, VP-Investor Relations & Communications

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences CEO David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among Caladrius Biosciences' employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Caladrius Biosciences' key competitors?

What other stocks do shareholders of Caladrius Biosciences own?

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

Who are Caladrius Biosciences' major shareholders?

Caladrius Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.53%), Renaissance Technologies LLC (2.63%), Geode Capital Management LLC (0.63%), State Street Corp (0.35%), Susquehanna International Group LLP (0.00%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends for Caladrius Biosciences
.

Which institutional investors are selling Caladrius Biosciences stock?

CLBS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sabby Management LLC, and Bank of Montreal Can.
View insider buying and selling activity for Caladrius Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Caladrius Biosciences stock?

CLBS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., Susquehanna International Group LLP, Millennium Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Caladrius Biosciences
or or view top insider-buying stocks.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $1.20.

How much money does Caladrius Biosciences make?

Caladrius Biosciences has a market capitalization of $71.42 million. The biotechnology company earns $-8,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Caladrius Biosciences have?

Caladrius Biosciences employs 24 workers across the globe.

When was Caladrius Biosciences founded?

Caladrius Biosciences was founded in 2006.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is www.caladrius.com.

Where are Caladrius Biosciences' headquarters?

Caladrius Biosciences is headquartered at 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at (908) 842-0100 or via email at [email protected].


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.